Treatment of pubertal gynaecomastia with testolactone
Authors:
- Milo ZachmannMZMilo Zachmann
- Urs EiholzerUEUrs Eiholzer
- Mariarosaria MuritanoMMMariarosaria Muritano
- Edmond A. WerderEWEdmond A. Werder
- Brigitte ManellaBMBrigitte Manella
- 1 December 1986
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 113 (4_Suppl) , S218-S226
Abstract
22 Boys with pubertal gynaecomastia (age 15.9+/−1.9 years) were treated with testolactone (450 mg daily by mouth) for 2 to 6 months without side-effects. The mean breast gland diameter regressed from 4.4 to 3.3, 3.2 cm, and 1.7 cm at 2,4, and 6 months, while pubic hair and testicular volume progressed normally. Plasma androstenedione increased from 5.4 to 73.1 nmol/l. Testosterone, DHEA, and oestrone increased less, and oestradiol remained unchanged. Androgen/oestrogen ratios increased (most marked change: androstenedione/oestrone from 15 to 140). LH (basal and maximum after LHRH) did not change, but FSH increased somewhat (basal 133 to 173, maximum 225 to 269 μg/l). Prolactin remained unchanged. It is concluded that testolactone, an inhibitor of steroid aromatization, is an effective and safe medical treatment for pubertal gynaecomastia.Keywords
This publication has 2 references indexed in Scilit:
- Aromatase Inhibition by Δ1-Testolactone Does Not Relieve the Gonadotropin-Induced Late Steroidogenic Block in Normal MenThe Journal of Clinical Endocrinology & Metabolism, 1985
- Metabolism in Vivo of Δ1-TestololactoneJournal of Biological Chemistry, 1961